Abstract

A quantum entanglement apparatus comprising: a first interference arrangement configured to receive photons with a first polarisation from a plurality of nodes; and a second interference arrangement configured to receive photons with a second polarisation from the plurality of nodes, wherein each of the first and second interference arrangements comprises: a plurality of inputs, each input configured to receive photons from a respective node of the plurality of nodes; a plurality of outputs; and a network of paths from each input to each output, wherein the network of paths is arranged such that a photon received at any input of the plurality of inputs may interfere with a photon received at any other of the plurality of inputs on one of the paths to one of the outputs, wherein the first and second interference arrangements are configured such that detection of photons at the outputs of the first and second interference arrangements enables entanglement between at least two nodes of the plurality of nodes.

IPC Classes  ?

• H04B 10/70 - Photonic quantum communication
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present invention provides a compound comprising: - one or more A cations, wherein the one or more A cations comprise a quaternary ammonium cation which comprises (a) at least one heteroatom selected from a halogen atom and an oxygen atom and/or (b) an organometallic complex; - one or more B cations, wherein the one or more B cations comprise a first B cation, Bn+, wherein n represents the oxidation state of the first B cation and n is an integer equal to or greater than 3; and - one or more X anions, wherein each X anion is a halide anion; wherein the compound has a non-centrosymmetric space group.

IPC Classes  ?

• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• C07F 17/02 - Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
• C07C 211/63 - Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms

Abstract

The present disclosure relates to apparatuses, classical modular processor units and methods for providing a decoder for finding a correction, C, to an error, E, detected in measurements of a qubit register received at intervals over time in a stream of successive measurement rounds. The decoder is implemented by a lattice or grid of identical classical modular processor units providing a viewing window of nodes and edges corresponding to a decoding graph for the quantum error correction code. Each classical modular processor unit independently and locally carries out a decoding cycle comprising a sequence of drop operation, a grow operation and a merge operation, by which a correction can be found to all errors arising in the qubit register within the viewing window in a computationally efficient, scalable manner that can clean the quantum computer faster than the error rate.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation

Abstract

The invention relates to WT1 specific and HLA-E restricted TCRs, as well as nucleic acids encoding the TCR and vectors comprising such nucleic acid. The invention also relates to uses of such a TCR in treating or preventing cancer.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/74 - Major histocompatibility complex [MHC]

Abstract

A device for detecting an analyte is provided. The device comprises: an optical system having a point spread function, a substrate, a passivation layer provided on the substrate, and a plurality of nanoholes distributed within the passivation layer.

IPC Classes  ?

• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G01N 21/51 - Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means

Abstract

The present invention relates to a conjugate of a specific cell penetrating peptide covalently linked to a therapeutic antisense oligonucleotide having a nucleotide repeat sequence, suitable for treatment of repeat expansion based disorders, in particular myotonic dystrophy (DM1).

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to a polynucleotide encoding or comprising a segmented poly(A) tail.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/67 - General methods for enhancing the expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The invention relates to antagonists for use in methods of treating cancer, wherein the cancer comprises an immunosuppressive tumour microenvironment comprising cancer cells and one or more types of non-cancerous cells. The invention also relates to bispecific agents useful in these methods, wherein the bispecific agents comprise a first antigen-binding domain that specifically binds CD115 or CD112 and a second antigen-binding domain that specifically binds CD3.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a bacterial process for the production of microbial storage lipids, such as wax esters, triacylclycerides, oils and polyhydroxyalkanoates, from readily available feedstocks derived from biomass. The feedstocks are rich in volatile fatty acids and ammonium, and are generated from biomass via the process of acidogenic fermentation. This allows for the preparation of microbial storage lipids from cheap and readily available biomass sources, such as plant or agricultural waste, or sewage. In particular, the present invention is directed to a process in which the carbon-to-nitrogen ratio of the composition containing volatile fatty acids and ammonium can be effectively controlled so as to optimise the yield of microbial storage lipid production from this process. The present invention also relates to microbial storage lipids that are obtainable by this process, and an apparatus for carrying out the process.

IPC Classes  ?

• C12P 7/62 - Carboxylic acid esters
• C12P 7/625 - Polyesters of hydroxy carboxylic acids
• C12P 7/6409 - Fatty acids

Abstract

The invention relates to computer implemented methods for determining the presence or risk of disease and/or vascular state in a subject. The method comprises (a) using data gathered from a computer tomography (CT) scan along a length of two or more blood vessels to determine: (i) a value for the radiodensity and/or one or more radiomic features of the perivascular tissue surrounding each blood vessel or segment thereof; (b) using the value for the radiodensity and/or one or more radiomic features of the perivascular tissue surrounding each blood vessel or segment thereof to determine the presence of disease and/or vascular state in each blood vessel, or segment thereof; and (c) generating an output value based on the number of vessels or segments thereof with disease and/or vascular state that indicates the subject's presence or risk of disease and/or vascular state. The invention also relates to computer program products, systems and machine learning or statistical modeals for performing the methods of the invention. Also disclosed is methods of training said machine learning or statistical models, and related systems.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The invention relates to antibodies which are capable of specifically binding to TCRbeta1 or TCRbeta2, and associated uses in diagnosis, prognosing and treatment of a disease or disorder associated with T-cell monotypia, or T cell-associated inflammation.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a culture medium comprising low glucose DMEM, L- glutamine, foetal bovine serum (FBS), antimicrobials and a trypsin inhibitor; the use of said culture medium for culturing mammalian cells and/or maintaining the viability of live tissue or tumour slices, optionally in a perfusion model; a method for 5 identifying a treatment for cancer utilising said culture medium; and a method for perfusion cell culture utilising said culture medium.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/09 - Tumour cells
• G01N 33/483 - Physical analysis of biological material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to fusion polypeptides and particles, particularly virus-like particles (VLPs), comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSPs) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the Hepatitis B virus surface antigen. The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use in the prevention of malaria.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61P 33/06 - Antimalarials

Abstract

This disclosure relates to GC-globulin or a variant thereof and a GLP1RA or a pharmaceutically acceptable salt thereof, for use in treating or preventing one or more of diabetes, obesity, MASLD and neurodegeneration.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/26 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Laser processing methods and apparatus are disclosed. In one arrangement, a method comprises using a laser beam to modify a sample along a processing trajectory in the sample by focusing the laser beam through a first face of the sample to a laser focus in the sample and providing relative movement between the laser focus and the sample to move the laser focus along the processing trajectory. The processing trajectory comprises a proximal portion and a distal portion. The proximal portion is nearer to a second face of the sample than the distal portion. The method comprises interacting with or adjusting the laser beam during processing of the proximal portion to reduce or prevent impingement of the laser beam onto the second face during the processing of the proximal portion.

IPC Classes  ?

• B23K 26/066 - Shaping the laser beam, e.g. by masks or multi-focusing by means of optical elements, e.g. lenses, mirrors or prisms by using masks
• B23K 26/53 - Working by transmitting the laser beam through or within the workpiece for modifying or reforming the material inside the workpiece, e.g. for producing break initiation cracks
• B23K 103/00 - Materials to be soldered, welded or cut

Abstract

The invention relates to agents specific for a heterocomplex comprising CD61 and CD103, and methods and uses of such agents.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells

Abstract

The invention relates to an electromicrobial system for synthesis of hydrogen, comprising: a gram-negative bacterial cell modified for synthesis of hydrogen, wherein the bacterial cell comprises: i) inner membrane-bound rhodopsin for proton-pumping, ii) membrane-bound hydrogenase, and iii) optionally an electron mediator located in the periplasm and/or on the outer membrane of the bacterial cell; and an electron source for donation of electrons to the bacterial cell.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 14/80 - Cytochromes
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/10 - Transferases (2.)
• C12N 9/90 - Isomerases (5.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

A negative electrode for a solid-state battery, the negative electrode having a first surface and thickness, the negative electrode for a solid-state battery comprising: a first phase including a first metallic element; a second phase distributed in the first phase, wherein the second phase is an intermetallic phase including the first metallic element and at least a second element, and wherein a diffusion coefficient of the first metallic element in the second phase is greater than a diffusion coefficient of the first metallic element in the first phase, and wherein there are a plurality of continuous pathways of the second phase each through at least half the thickness of the negative electrode.

IPC Classes  ?

• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

A circuit quantum electrodynamics, QED, component having a geometrical arrangement based on a geometrically symmetric arrangement that enables the formation of degenerate modes in a circuit QED device, wherein the geometrical arrangement comprises a symmetry breaking perturbation relative to the geometrically symmetric arrangement such that the component is configured to generate one or more engineered interference effects and/or additional functionality in the circuit QED device.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• H10N 60/80 - Constructional details
• H10N 69/00 - Integrated devices, or assemblies of multiple devices, comprising at least one superconducting element covered by group

Abstract

A time-varying array of controllable elements configured to receive an input signal in the form of electromagnetic radiation impinging on the array, wherein: each controllable element is configured to have a non-linear response to the input signal; and at least a subset of the controllable elements is configured to: adjust a permeability response of the array; and modulate an input signal receivable at the array based on the adjusted permeability response in order selectively to generate one or more output signals in a range of one or more corresponding target directions, each output signal comprising electromagnetic radiation.

IPC Classes  ?

• H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
• H01Q 25/00 - Antennas or antenna systems providing at least two radiating patterns

Abstract

According to various examples of the present disclosure, there is provided a machine learning image segmentation model for automatically identifying and segmenting structural features of a vessel tree from image frames. The model comprises a 3D encoder and 2D decoder, the 3D encoder and 2D decoder connected by at least one interlinked convolution node and a plurality of temporal extraction nodes therebetween. The model is configured to identify and segment structural features of a vessel tree from the plurality of image frames, by the model being configured to: receive a plurality of image frames as an input to the 3D encoder; provide an output of the 3D encoder as an input to the plurality of temporal extraction nodes to extract temporal information; generate, by the plurality of temporal extraction nodes, a 2D temporal output based on the extracted temporal information; provide the generated 2D temporal output to the at least one interlinked 2D convolution node and 2D decoder; generate, at the 2D decoder, a combined temporal output based on an output of the at least one interlinked 2D convolution node and at least one temporal extraction node, wherein the combined temporal output represents a predicted segmentation of the vessel; and generate an output representative of the segmented structural features of the vessel tree based on the predicted segmentation.

IPC Classes  ?

• G06T 7/11 - Region-based segmentation
• G06T 7/174 - SegmentationEdge detection involving the use of two or more images

Abstract

The present invention relates to the generation of organoids using granular hydrogel, which is a compacted assembly of hydrogel microparticles.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

A large language model system is disclosed. In one arrangement the system comprises: a data processing system configured to implement a first large language model, a second large language model, and a third large language model, wherein the data processing system is configured to: receive inquiry data representing a user inquiry; input at least the inquiry data to the first large language model and receive a first data output as a corresponding output from the first large language model; input at least the first data output and a knowledge graph to the second large language model and receive a second data output as a corresponding output from the second large language model; input at least the first data output, the second data output, and the inquiry data to the third large language model and receive a third data output as a corresponding output from the third large language model; and output the third data output as an answer to the user inquiry.

IPC Classes  ?

• G06F 16/3329 - Natural language query formulation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to polypeptides for treatment or prevention of malaria.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens

Abstract

A method of forming a device comprising: providing a device substrate; providing a flexible multilayer substrate having an insulating layer and an electrically conductive layer formed on the insulating layer; forming a patterned layer on a surface of the electrically conductive layer, thereby to provide protected and unprotected regions of the electrically conductive layer; etching the unprotected regions of the electrically conductive layer, thereby to form one or more electrically conductive features on the insulating layer of the flexible multilayer substrate; removing the patterned layer; and conformally applying the one or more electrically conductive features formed on the insulating layer of the flexible multilayer substrate to a target surface of the device substrate.

IPC Classes  ?

• H03H 3/08 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of resonators or networks using surface acoustic waves
• H03H 3/06 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of magnetostrictive resonators or networks
• H03H 9/05 - Holders or supports
• H03H 9/08 - Holders with means for regulating temperature

Abstract

Methods of obtaining information about entities in a liquid sample are disclosed. An observation volume is defined by a pair of confinement surfaces of a reservoir containing a sample. The confinement surfaces define a plurality of traps. Information about residence times of target entities in the traps is obtained and used to determine information about the target entities. A ratio of an average separation between the confinement surfaces outside of the traps and a maximum dimension of each target entity is equal to or less than 50.

IPC Classes  ?

• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials

Abstract

A method of correcting for an aberration in an optical system (600) comprising an imaging detector (634) having a focussing lens (608) and a spatial light modulator (610) is provided. The method comprises receiving an image. The method comprises determining an intensity aberration compensation from the collected image. The method comprises controlling the spatial light modulator (610) to reduce the intensity aberration by applying the intensity aberration compensation.

IPC Classes  ?

• G02B 26/06 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the phase of light
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,

Abstract

Methods and apparatus for determining a control sequence for execution on a quantum computer and for determining a sequence of pulses of radiation. The method includes receiving a target quantum operation, determining a circuit or pulse library comprising a plurality of quantum circuits or pulses, each of which approximate the target operation, determining a solution weight vector which synthesises the target operation when applied in a weighted summation over the circuit or pulse library and which satisfies a minimum condition, determining a probability associated with each quantum circuit or pulse in the library, and performing a plurality of selections of a quantum circuit or pulse from the library according to the probability distribution to form a control sequence or sequence of pulses.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers

Abstract

Disclosed herein is an in-situ leaching system comprising: a lixiviant source; and an injection well arranged to receive a leaching solution at ground level and to inject the received leaching solution into underground glassy volcanic rock; wherein: the leaching solution comprises lixiviant from the lixiviant source; and the leaching solution is for leaching the underground glassy volcanic rock.

IPC Classes  ?

• B01D 11/02 - Solvent extraction of solids
• C22B 3/02 - Apparatus therefor
• C22B 3/04 - Extraction of metal compounds from ores or concentrates by wet processes by leaching
• C22B 3/08 - Sulfuric acid
• C22B 3/12 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic alkaline solutions
• C22B 3/20 - Treatment or purification of solutions, e.g. obtained by leaching
• C22B 19/00 - Obtaining zinc or zinc oxide
• C22B 34/14 - Obtaining zirconium or hafnium
• C22B 34/24 - Obtaining niobium or tantalum
• C22B 59/00 - Obtaining rare earth metals
• E21B 34/16 - Control means therefor being outside the borehole
• E21B 43/12 - Methods or apparatus for controlling the flow of the obtained fluid to or in wells
• E21B 43/28 - Dissolving minerals other than hydrocarbons, e.g. by an alkaline or acid leaching agent
• F24T 10/20 - Geothermal collectors using underground water as working fluidGeothermal collectors using working fluid injected directly into the ground, e.g. using injection wells and recovery wells
• F24T 10/30 - Geothermal collectors using underground reservoirs for accumulating working fluids or intermediate fluids
• F24T 50/00 - Geothermal systems
• F24V 99/00 - Subject matter not provided for in other main groups of this subclass
• E21B 43/29 - Obtaining a slurry of minerals, e.g. by using nozzles
• F24T 10/00 - Geothermal collectors

Abstract

The disclosure relates to methods of manufacturing a composite object. A disclosed method comprises positioning a stack (2) of layers against a non-planar moulding surface (4) of a moulding device and curing the stack of layers to form a composite object (8). Before the curing, the stack comprises a set of fibre-matrix layers (21) and a set of isotropic layers (22).

IPC Classes  ?

• B29C 70/08 - Fibrous reinforcements only comprising combinations of different forms of fibrous reinforcements incorporated in matrix material, forming one or more layers, with or without non-reinforced layers
• B29C 70/88 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts characterised primarily by possessing specific properties, e.g. electrically conductive or locally reinforced
• B32B 15/14 - Layered products essentially comprising metal next to a fibrous or filamentary layer
• B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B32B 1/08 - Tubular products
• B32B 15/20 - Layered products essentially comprising metal comprising aluminium or copper
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• H05H 7/00 - Details of devices of the types covered by groups
• H05H 7/14 - Vacuum chambers

Abstract

The present disclosure relates to methods of operating a parametric amplifier. In one arrangement, a parametric amplifier is provided that comprises a nanostructure suspended between an input electrode and an output electrode. The nanostructure is spaced apart from a control electrode and configured such that a vibration of the nanostructure varies a distance between at least a portion of the nanostructure and the control electrode. A single-electron transistor is formed that comprises the nanostructure as a conducting island of the single-electron transistor. An oscillatory input signal is applied to the input electrode. An oscillatory control signal is applied to the control electrode. The control signal comprises a DC component that defines a potential of the island and an electrostatic tensioning of the nanostructure and an oscillatory pump component that provides an amplified version of the input signal in an output signal provided at the output electrode.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention provides means and methods for administering agents, including therapeutic agents, to the retina of a subject The methods comprise injecting the agent directly into the optic nerve.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61F 9/007 - Methods or devices for eye surgery

Abstract

The invention relates to polynucleotides comprising sequences that flank variable regions, such as barcode sequences (BCs) and unique molecular identifier sequences (UMIs). The invention also relates to methods of delimiting the BC and/or the UMI in sequencing reads of said polynucleotides.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

in vivoin vivo. The invention also relates to coatings comprising an amino-functionalised graphene oxide; devices coated in an amino-functionalised graphene oxide; coating solutions; methods of coating a device; and an amino-functionalised graphene oxide.

IPC Classes  ?

• A61K 33/44 - Elemental carbon, e.g. charcoal, carbon black
• A61L 31/00 - Materials for other surgical articles
• C08K 3/04 - Carbon

Abstract

22, which may be further processed to MgO for use as an additive in green cement. As part of the process, the pH of seawater is adjusted to pH 9.0- 10.5 (e.g., pH 9.5-10.5) in order to precipitate dissolved inorganic carbon, after which the resulting low carbon seawater is subjected to a reverse osmosis process. The pH of the permeated brine is then adjusted to pH 10.0-13.25 (e.g., pH 11.5-13.25) in order to precipitate Mg2+222 and/or to produce NaOH, which can be advantageously used in the aforementioned precipitation steps.

IPC Classes  ?

• C02F 9/00 - Multistage treatment of water, waste water or sewage
• C01F 5/14 - Magnesium hydroxide
• B01D 61/02 - Reverse osmosisHyperfiltration
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
• C02F 1/66 - Treatment of water, waste water, or sewage by neutralisationTreatment of water, waste water, or sewage pH adjustment
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

An electrochemical battery, comprising a sulphur cathode; a lithium anode; and a solid electrolyte between the sulphur cathode and the lithium anode, wherein the solid electrolyte has an argyrodite-type structure and comprises lithium, phosphorus, sulphur, and a halogen.

IPC Classes  ?

• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials
• C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus
• C01D 15/04 - Halides

Abstract

abcc wherein: [A] comprises one or more A cations; [M] comprises one or more M cations which are metal or metalloid cations; [X] comprises one or more X anions; a is a number from 1 to 6; b is a number from 1 to 6; and c is a number from 1 to 18, and wherein the passivating agent comprises an organic compound, wherein the organic compound comprises a silane moiety and (a) does not comprise an amine moiety, or (b) comprises an amine moiety which is a secondary amine, a tertiary amine or a quaternary amine, or the passivating agent comprises a dimer or a polymer of the organic compound. The invention also provides the use of the above-defined passivated A/M/X material as a sensitizer in a photovoltaic device. The present invention also relates to processes for producing a passivated A/M/X material and then (a) producing a photovoltaic device comprising the passivated A/M/X material or (b) using the passivated A/M/X material as a sensitizer in a photovoltaic device.

IPC Classes  ?

• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers

Abstract

The invention relates to methods for diagnosing inflammatory bowel disease (IBD) and for distinguishing between common gastrointestinal disease (principally functional bowel disease/irritable bowel syndrome and coeliac disease) and IBD, especially in children and in subjects with normal levels of C-reactive protein. The methods are based on measuring the methylation level of at least one CpG site in at least one gene.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to identifying one or more anomalous monomers in a polymer. This invention also relates to a method of preparing control data for use in a method of identifying anomalous monomers in a polymer. The invention also relates to an apparatus to perform the method and a system comprising this apparatus and a nucleic acid sequencer.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6869 - Methods for sequencing
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16B 40/20 - Supervised data analysis

Abstract

The present invention relates to processes for the oxidation of sesquiterpenes comprising fused 5- and 7-membered rings using mutant Cytochrome P450 family 102A sub-family member (CYP102A) enzymes. The invention also relates to mutant CYP102A enzymes, polynucleotides encoding the enzymes, cells expressing the enzymes, transgenic animals or plants comprising the enzymes, and compounds produced by the processes.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C07C 13/32 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings

Abstract

The present invention relates to methods comprising exposure of a rotifer to a microbe. The invention also relates to compounds, polynucleotides, methods of therapy and methods of controlling microbial disease in plants.

IPC Classes  ?

• A01P 3/00 - Fungicides
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 7/66 - Gramicidins S, CTyrocidins A, B, CRelated peptides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

P_AP_AP_BP_BP_CP_CP_AP_BP_CP_AP_CP_C having a second, arbitrary polarisation.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour

Abstract

An electrode material for a solid-state battery is described. The electrode material comprises an alloy comprising lithium and magnesium, wherein the alloy has a total amount of magnesium of less than 5.0 at.%. An electrode, a solid-state battery, uses of the electrode material or the electrode and a method of producing an electrode material or an electrode are also described.

IPC Classes  ?

• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/66 - Selection of materials
• H01M 10/0562 - Solid materials

Abstract

xyz22 (1) wherein M is a transition metal selected from manganese, nickel, iron, titanium, copper and a combination of two or more thereof; and x, y and z satisfy the following relationships: (i) 0.5 ≤ x ≤ 1.0; (ii) 0.01 ≤ y ≤ 0.25; and (iii) y + z = 1.0. Also described is a positive electrode material, a positive electrode and a device.

IPC Classes  ?

• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• C01G 53/51 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese of the type (MnO2)n-, e.g. Li(NixMn1-x)O2 or Li(MyNixMn1-x-y)O2 containing sodium

Abstract

The invention relates to methods of treating, diagnosing or preventing TDP-43 proteinopathies, selecting patients with TDP-43 proteinopathies for treatment, and agents for use in such methods, wherein the agents modulate ATG4B expression or activity.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention relates to a cosmetic composition (e.g. sunscreen composition), and to a method for making the cosmetic composition.

IPC Classes  ?

• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• A61K 8/26 - AluminiumCompounds thereof
• A61K 8/27 - ZincCompounds thereof
• A61K 8/29 - TitaniumCompounds thereof
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations

Abstract

The present invention relates to a two-part linker comprising a peptide (peptide tag) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly in low temperature and low pH conditions. Recombinant or synthetic polypeptides comprising the polypeptide or peptide tag, nucleic acid molecules encoding the polypeptide, peptide tag or recombinant polypeptides, vectors comprising said nucleic acid molecules, and host cells comprising said vectors and nucleic acid molecules are provided herein. A kit and apparatus comprising said polypeptide and peptide tag and various methods and uses of the polypeptide and peptide tag are also provided.

IPC Classes  ?

• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof

Abstract

Probes and systems for measuring flow are provided. In one arrangement, a pitot tube extends parallel to a probe axis and defines a first probe opening at a distal end. A shroud extends axially beyond the distal end to inhibit oblique flow into the first probe opening. The shroud defines a flow passage between the shroud and the pitot tube. The shroud comprises a distal surface defining one or more second probe openings. The distal surface has an outer portion facing at least partly in a radially outward direction. The one or more second probe openings are at least partially defined in the outer portion.

IPC Classes  ?

• G01P 5/165 - Arrangements or constructions of Pitot tubes
• B64D 43/02 - Arrangements or adaptations of instruments for indicating aircraft speed or stalling conditions
• G01F 1/46 - Pitot tubes

Abstract

A component mounting assembly for mounting a component in a mount structure, the mounting assembly comprising a support body arranged to be connected to the component or to the mount structure; an even number N of beams, N being at least four, wherein said beams are arranged in a loop either outside the support body in the case that the support body is arranged to be connected to the component; or inside the support body in the case that the support body is arranged to be connected to the mount structure; wherein adjacent beams in the loop are connected by respective hinge joints that permit relative rotation of the adjacent beams connected thereby, the beams being integrally formed with each other and the hinge joints being integral connections having a compliance that permits said relative rotation of the adjacent beams connected thereby; wherein each beam is connected to the support body by a respective pivot joint that permit relative rotation of the respective beam and the support body, the beams and the support body being integrally formed, and the pivot joints being integral connections having a compliance that permits said relative rotation of the respective beam and support body; wherein a plurality of said beams comprise contact surfaces arranged to contact either an internal surface of the mount structure in the case that the support body is arranged to be connected to the component; or an external surface of the component the in the case that the support body is arranged to be connected to the mount structure, such that the contact surfaces provide a reaction force to the beams on which they are provided that induces relative rotation of adjacent beams in alternate rotational directions at successive pivot joints around the loop, to thereby align the component relative to the mount structure.

IPC Classes  ?

• G02B 7/00 - Mountings, adjusting means, or light-tight connections, for optical elements

Abstract

An ion trap assembly comprising an ion trap body, a component, and a compliant structure, wherein the compliant structure is a passive alignment structure configured to positionally retain the component relative to the body. In one embodiment, a cantilever beam positionally retains an optical fibre component relative to a groove. This avoids the drawbacks of gluing optical components.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

Examples disclosed herein provide computer-implemented methods and apparatus of generating a realistic front view, FV, of an environment. A method comprises: receiving, as input, a latent floorplan indicative of an environment, the latent floor plan representational of a semantic birds-eye-view, BEV, of the environment; obtaining a volumetric representation of the environment based on the latent floorplan using a neural radiance field, NeRF; obtaining a semantic FV of the environment by volume rendering based on the volumetric representation of the environment; obtaining a realistic FV of the environment based on the semantic FV using a diffusion technique; and outputting the realistic FV of the environment.

IPC Classes  ?

• G06T 15/20 - Perspective computation
• G06T 17/00 - 3D modelling for computer graphics
• G06T 15/08 - Volume rendering

Abstract

P360293WO 44 Abstract Provided is a compound of formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof which can be used as a radiopharmaceutical agent for the imaging and/or treatment of diseases. Also provided are conjugates of the compound of formula (I) with radionuclides and uses of the conjugates and compositions comprising the conjugates for 5 the imaging and/or treatment of diseases. (I) [Figure 1]

IPC Classes  ?

• C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

Abstract

The present invention relates to novel compounds and methods. The invention particularly provides a compound that finds use in the treatment of cancer by selectively degrading under hypoxic conditions a therapeutic target protein of interest. The compound is a hypoxia-activated proteolysis targeting chimera (hypoxia-activated PROTAC; HAP-TAC).

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 495/14 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to antibodies for treatment or prevention of malaria.

IPC Classes  ?

• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A61P 33/06 - Antimalarials

Abstract

The invention relates to a power unit comprising a series of droplets, a method of producing such a power unit, a method of activating such a power unit, an active power unit obtainable from the power unit, a device comprising the power unit or active power unit, a method of generating electric current using the power unit or active power unit, and method of modulating the activities of one or more cells or tissues using the power unit or active power unit.

IPC Classes  ?

• H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elementsFuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen
• H01M 6/26 - Cells without oxidising active material, e.g. Volta cells
• H01M 10/02 - Details
• H01M 10/04 - Construction or manufacture in general
• H01M 10/36 - Accumulators not provided for in groups
• H01M 10/38 - Construction or manufacture
• H01M 14/00 - Electrochemical current or voltage generators not provided for in groups Manufacture thereof
• H01M 6/30 - Deferred-action cells

Abstract

The present invention relates to a bivalent polypeptide scaffold that facilitates sequential (e.g. stepwise) assembly of molecules to form a single structure. Nucleic acid molecules encoding the polypeptide scaffold, vectors comprising said nucleic acid molecules, and host cells comprising said vectors and nucleic acid molecules are also provided. Kits comprising said polypeptide scaffold and/or nucleic acid molecules/vectors are also provided. Further products comprising said polypeptide scaffold and uses of the polypeptide scaffold of the invention are also provided, e.g. methods of assembling bispecific binding structures.

IPC Classes  ?

• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/46 - Hybrid immunoglobulins
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof

Abstract

Described is a nanopore that is selectively convertible between an open form and a closed form using light, a method for producing such a nanopore, a method of modulating the flow of one or more substances through the nanopore, the use of the nanopore in modulating ionic flow across an amphiphilic membrane, a device comprising the nanopore, use of the nanopore as an ionotronic component, use of the nanopore in bio-computation and/or bioionotronics, a method of transmitting information using the nanopore, and method of receiving information comprising the nanopore, and an ionotronic component comprising the nanopore.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6869 - Methods for sequencing
• G06N 3/00 - Computing arrangements based on biological models

Abstract

Methods and systems are disclosed for detecting characteristics of particles or particle environments. In one arrangement, trajectory data is received that represents detected diffusion trajectories of particles in one or more respective particle environments. Each detected diffusion trajectory comprises a sequence of trajectory segments. Characteristics of particles and/or of the one or more particle environments of the particles are identified by analysing the trajectory segments.

IPC Classes  ?

• G01N 15/1433 - Signal processing using image recognition
• G06T 7/20 - Analysis of motion

Abstract

Examples relate to an apparatus, for example, a Tensor Processor Unit, for processing, for example, multiplying, first and second Matrix Product States, the apparatus comprising circuitry to: a. receive, or store in memory, first matrix product state data (MPS 1) associated with a first matrix product state; the first matrix product state data comprising first tensor component data associated with the tensor components of the first matrix product state; b. receive, or store in memory, second matrix product state data (MPS 1) associated with a second matrix product state; the second matrix product state data comprising second tensor component data associated with the tensor components of the second matrix product state; c. processing corresponding tensor component data of the first and second matrix product state data to produce tensor contraction data representing a contraction of the tensor components associated with the corresponding tensor component data of the first and second matrix product state data; d. processing copy tensor data representing a copy tensor and the tensor contraction data to produce respective tensor component data; the respective tensor component data representing a contraction of the copy tensor and the contraction of the tensor components associated with the corresponding tensor component data of the first and second matrix product states; and e. associating, or storing in memory, the respective tensor component data with a corresponding tensor component data position of result data representing a resultant matrix product state associated with the processing/multiplying the first and second Matrix Product States.

IPC Classes  ?

• G06F 9/30 - Arrangements for executing machine instructions, e.g. instruction decode
• G06F 17/16 - Matrix or vector computation

Abstract

A parametric system (1) comprising two or more parametric devices (3,4,21,22), arranged in parallel to each other, the parametric system (1) comprising a first input arranged to receive an input signal, means (2, 20, 43, 83) to split the input signal into two or more signal branches, wherein each signal branch is provided to one of the parametric devices (3,4,21,22), means to supply at least one pump signal to each of the parametric devices alongside the input signal, such that each signal branch undergoes an n-wave mixing process at the corresponding parametric device (3,4,21,22), means (16, 20', 20", 27, 48, 70, 84) to combine the output of the parametric devices (3,4,21,22) into an output signal, wherein the output of each parametric device (3,4,21,22) includes signal components including: an amplified signal portion, one or more pump signal and an idler signal; and means to control the relative phase of the pump signals and/or signal branches at each parametric device (3,4,21,22) such that the output signal includes at least a first output signal component formed by the constructive interference of a signal component from each parametric device (3,4,21,22) and a second output signal component formed by the destructive interference of a signal component from each parametric device (3,4,21,22).

IPC Classes  ?

• H03D 7/00 - Transference of modulation from one carrier to another, e.g. frequency-changing
• G02F 1/39 - Non-linear optics for parametric generation or amplification of light, infrared, or ultraviolet waves
• H03D 7/14 - Balanced arrangements

Abstract

Systems and methods for generating stimulation signals for brain or nerve stimulation are disclosed. In one arrangement, a signal generation unit generates a stimulation signal and transmits the stimulation signal to a stimulation unit. The stimulation unit applies the stimulation to a biological system. The stimulation signal is defined by at least one stimulation parameter. A data receiving unit receives time series biomarker data comprising measurement samples representing one or more biomarkers indicative of a condition of the biological system that is affected by applied stimulation based on the stimulation signal. A controller controls generation of the stimulation signal based on the received biomarker data. The controller uses a model of the biological system to estimate an optimal value of the at least one stimulation parameter using the biomarker data. The model defines strengths of contribution of measurement samples to the estimate based on the times at which the measurement samples were obtained.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

The invention provides an antigen binding polypeptide which is capable of binding to a HLA- E:peptide complex, wherein the antigen binding polypeptide is a HPV-specific TCR or CAR.

IPC Classes  ?

• C07K 14/725 - T-cell receptors

Abstract

Methods and systems for determining neurological health information about a subject are disclosed. In one arrangement, a plurality of training data units are received from training subjects, each training data unit comprising movement data and health category data. The movement data is derived from measurement of training movements. The health category data defines a health category of the training subject. A neural network is trained using the training data units. Training movements are represented by time series data defining a waveform. The trained neural network generates an encoded representation of the waveform of each training movement. A classifying machine learning model is trained to classify the waveforms into corresponding health categories using the generated encoded representations and health category data as training data. Movement data is received from a further subject and the trained neural network and the trained classifying machine learning model are used to determine the health category data of the further subject using the received movement data.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

There is provided an optical fibre comprising a first portion and a second portion, wherein: the second portion is a void portion comprising one or more voids, wherein the one or more voids extend longitudinally along the length of the optical fibre within the void portion; the first portion and the second portion are substantially mode-matched; and the one or more voids are at least partially filled with a filler having a material property different to the material property of a material of the optical fibre.

IPC Classes  ?

• G02B 6/02 - Optical fibres with cladding
• G01K 11/3206 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres at discrete locations in the fibre, e.g. using Bragg scattering
• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis

Abstract

The present invention relates to polynucleotides comprising a plant cell promoter element operatively linked to a nucleotide sequence that encodes a water-forming oxidase. The invention also relates to methods for increasing the growth and yield of plants.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Processes for the preparation of fluorochemicals are described, in which a fluoride source is pulverised together with an activator and optionally a sequestrant. Fluorochemicals resulting from the processes are also described.

IPC Classes  ?

• C01D 3/02 - Fluorides
• C01D 15/04 - Halides
• C01F 5/02 - Magnesia
• C01F 11/00 - Compounds of calcium, strontium, or barium
• C01F 11/10 - Oxides or hydroxides from sulfides
• C01G 21/06 - Lead monoxide [PbO]
• C01G 21/22 - PlumbatesPlumbites
• C01G 23/00 - Compounds of titanium
• C01G 39/00 - Compounds of molybdenum
• C01G 41/00 - Compounds of tungsten

Abstract

The present invention relates to processes for preparing fluorochemicals. The present invention also relates to the fluorochemicals resulting from the processes of the present invention. The processes of the present invention can avoid the need to use hydrofluoric acid as an intermediate for fluorochemical production.

IPC Classes  ?

• C07B 39/00 - Halogenation
• C07C 25/13 - Monocyclic aromatic halogenated hydrocarbons containing fluorine
• C07C 247/16 - Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
• C07F 5/02 - Boron compounds
• C07F 7/12 - Organo silicon halides
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups

Abstract

According to examples of the invention, there is provided a method of image generation using magnetic resonance imaging, MRI, with echo-planar imaging, EPI. The method comprises transmitting a RF pulse (411) to a subject in a static magnetic field in the presence of an applied spatial magnetic field gradient; receiving magnetic resonance, MR, signals; sampling the received MR signals to acquire a plurality of temporarily adjacent EPI volumes and generating a k space map (601) for the plurality of EPI volumes by: applying an oscillating readout gradient (417) over each of the plurality of EPI volumes to obtain readout data along a readout axis; and applying a phase encoding gradient (415), while applying the oscillating readout gradient (417), such that trajectory lines of readout data for each of the plurality of EPI volumes are interleaved in k space using a periodic rewinding pattern along a phase encoding axis. The method comprises dividing the generated k space map (601) into a plurality of k space sub-maps (603a, 603b, 603c), each of the plurality of k space sub-maps (603a, 603b, 603c) associated with one of the plurality of EPI volumes and applying an optimisation function utilising shared information across the plurality of k space sub-maps (603a, 603b, 603c) to jointly reconstruct k space data; and generating an image (621) based on the jointly reconstructed k space data.

IPC Classes  ?

• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

Provided herein are method for detecting the interaction of a protein of interest and an analyte. Also provided herein are polypeptides, nucleic acids, cells and kits suitable for attaching a protein of interest to a cell. Also provided herein are cells and populations of cells comprising a protein of interest and methods for preparing said cells and populations thereof.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 5/07 - Animal cells or tissues
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

The invention relates to a composition comprising OMVs obtained from a modified Neisseria gonorrhoeae strain expressing a PorB variant, methods for preparing said composition, and its uses including vaccines.

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides a rhodium-catalysed, enantioselective process for preparing a compound of formula (IV), as defined herein, comprising a step of reacting a compound of formula (V), as defined herein, with a compound of formula (V)I, as defined herein, in the presence of a rhodium species, a chiral ligand and optionally a base. Further aspects of the present invention relate to the preparation of a piperidine compounds of formula (I), as defined herein, utilising said enantioselective a rhodium-catalysed reaction. Also provided are intermediates of formula (IV) and sub-formulae thereof.

IPC Classes  ?

• C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 211/16 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
• C07D 211/20 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms
• C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
• C07D 211/24 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by sulfur atoms to which a second hetero atom is attached
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

A method of monitoring a transmission includes obtaining one or more values of bit error rate (BER) of the transmission received at a receiver; and determining that the transmission has been intercepted based on a deviation of the obtained bit error rate value from an expected bit error rate value.

IPC Classes  ?

• H04L 9/40 - Network security protocols
• H04L 9/08 - Key distribution

Abstract

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

In one arrangement, an apparatus comprises an elongate sheath insertable through the vascular system to a target site. A filter arrangement extends from a distal end of the sheath and comprises a porous membrane switchable between a radially contracted state and a radially expanded state. The radially expanded state is such as to span a cross- section of a blood vessel to block debris from travelling past the porous membrane. A filter actuation system hydraulically switches the porous membrane between the radially contracted state and the radially expanded state.

IPC Classes  ?

• A61F 2/01 - Filters implantable into blood vessels

Abstract

The present invention relates to novel systems, polypeptides, compounds and methods. The invention provides an inducible degron for target-specific protein degradation.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Methods and apparatus for classifying phytoplankton cells are described. In some examples, the methods comprise acquiring transient data indicative of a change in luminescence of the phytoplankton cell after exposure to excitation radiation and classifying the phytoplankton cell using the transient data as an input to a trained classifier, wherein the classifier is trained using classified transient data for a plurality of phytoplankton cells.

IPC Classes  ?

• G06V 10/143 - Sensing or illuminating at different wavelengths
• G06V 10/60 - Extraction of image or video features relating to illumination properties, e.g. using a reflectance or lighting model
• G06V 10/62 - Extraction of image or video features relating to a temporal dimension, e.g. time-based feature extractionPattern tracking
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

Methods and apparatus for providing embolic protection during a transcatheter operation are disclosed. In one arrangement, an apparatus comprises an elongate sheath insertable through the vascular system to a target site. A filter arrangement extends from a distal end of the sheath. The sheath is switchable between a radially contracted state and a radially expanded state. The sheath in the radially expanded state defines a central lumen for allowing insertion of a device for performing a transcatheter operation. The filter arrangement comprises a porous membrane switchable between a radially contracted state and a radially expanded state. The radially expanded state is such as to span a cross-section of a blood vessel to block debris from travelling past the porous membrane. A filter actuation system switches the porous membrane between the radially contracted state and the radially expanded state.

IPC Classes  ?

• A61F 2/01 - Filters implantable into blood vessels

Abstract

A device comprising a diamond substrate, wherein: the substrate comprises a device track formed by modifying the structure of carbon within the substrate; and electrical conductivity along the device track is asymmetric. A method of manufacturing a device, the method comprising: forming a device track having asymmetric electrical conductivity along the device track by modifying the structure of carbon within a diamond substrate.

IPC Classes  ?

• H01L 21/268 - Bombardment with wave or particle radiation with high-energy radiation using electromagnetic radiation, e.g. laser radiation
• H01L 29/16 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only elements of Group IV of the Periodic System in uncombined form
• H01L 29/861 - Diodes

Abstract

A multiplexer is disclosed for multiplexing signals from a plurality of readout resonators of a circuit QED device. In one arrangement, the multiplexer comprises a cavity resonator system comprising one or more inner conductors and an outer conductor. The outer conductor comprises a plurality of openings and surrounds the one or more inner conductors in directions other than towards the openings. A signal port system is coupled to the cavity resonator system and configured to receive multiplexed signals from the readout resonators. The readout resonators are provided in a common plane. One of the inner conductors is configured to capacitively couple to the readout resonators through respective openings in a direction extending perpendicularly or obliquely relative to the plane.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A carbon sequestration unit (1) comprises a support layer (10) configured to support a photosynthetic organism (12), a growth substrate (14) for the photosynthetic organism disposed along the support layer, and an irrigation pipe (16) configured to release water along its length for irrigating the photosynthetic organism. The support layer has a shape that is convoluted in three dimensions allowing for growth surface maximisation compared to the land on which the carbon sequestration unit is deployed.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/85 - Biological processes with gas-solid contact

Abstract

This disclosure teaches multi-classification of endoscopic imaging using a segmentation neural network. The network is trained on imaging data using a novel loss function with components of both focal and boundary loss. During a lithotripsy procedure, images are received by a deployed endoscopic probe. Based on the received imaging data and inference data from its prior learning, the segmentation neural network identifies renal calculi and surgical instruments within the imaging data. The imaging data is modified and displayed to assist the lithotripsy procedure.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• A61B 5/20 - Measuring urological functions
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

This disclosure teaches determining a renal calculus size based on calibration data generated from an endoscopic imager. During a lithotripsy procedure, images are received by a deployed endoscopic probe. Based on the received imaging data, the generated calibration data, and known properties of the endoscopic probe, one or more renal calculi in the images are identified and sized. The determined size values are displayed with the images of the renal calculi.

IPC Classes  ?

• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/307 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the urinary organs, e.g. urethroscopes, cystoscopes
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

22 (or CO) to methanol.

IPC Classes  ?

• B01J 21/08 - Silica
• B01J 23/80 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with zinc, cadmium or mercury
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/03 - PrecipitationCo-precipitation
• C07C 29/153 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used

Abstract

Provided herein are methods of characterising a peptide, polypeptide or protein and of characterising one or more proteoforms of a peptide, polypeptide or protein, using nanopores. Also provided herein are associated systems.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/487 - Physical analysis of biological material of liquid biological material

Abstract

The present invention relates to a sensing assembly comprising a solid support and a receptor, wherein the sensing assembly is suitable for detecting sulphide. The present invention also relates to methods of detecting sulphide using the sensing assembly of the present invention.

IPC Classes  ?

• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
• C07F 5/02 - Boron compounds
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

There is provided a method for determining a location of a source of neural activity signals within a brain. The method comprises measuring electrical signals from respective contacts of a plurality of contacts located at known relative positions within the brain, processing the electrical signals to detect neural activity signals in the electrical signals from the respective contacts, determining timings of the detected neural activity signals, and determining the location of the source of neural activity within the brain relative to the plurality of contacts by fitting a source model to the timings relative to each other, wherein the source model models an arrangement of the source of the neural activity signals and models the neural activity signals as travelling waves that propagate through the brain. The location of the source of neural activity can be used to guide optimal delivery of deep brain stimulation.

IPC Classes  ?

• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/37 - Intracranial electroencephalography [IC-EEG], e.g. electrocorticography [ECoG]
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

A hypoxia inducible factor prolyl hydroxylase inhibitor (PHD inhibitor) for use in the treatment of blood cancer.

IPC Classes  ?

• C07D 239/54 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/415 - 1,2-Diazoles
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to antigens, antibodies and vaccines for treatment or prevention of malaria.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61P 33/06 - Antimalarials
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A compound which is a substituted azine of formula (I), a substituted pyrimidine of formula (IV), or a pharmaceutically acceptable salt thereof

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/415 - 1,2-Diazoles
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention relates to compounds of formula (I) which are inhibitors of 3C like proteases, pharmaceutical compositions comprising such compounds, and the compounds for use in methods of treating viral infections caused by viruses comprising 3C-like proteases.

IPC Classes  ?

• C07D 207/20 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention relates to a peptide mass tag for recovery and identification of target proteins by mass spectrometry. The invention further relates to fusion polypeptides including the peptide mass tag and a method of analysing a target protein comprising use of the peptide mass tag.

IPC Classes  ?

• G01N 33/563 - ImmunoassayBiospecific binding assayMaterials therefor involving antibody fragments
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides methods for prognosing an increased risk of early onset preeclampsia (EOPE) in a pregnant subject before the disease onset. The methods comprises quantifying small extracellular vesicles that express pairs of biomarkers selected from CD10, CD63 and placental alkaline phosphatase (PLAP) in a sample obtained from the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 9/12 - Antihypertensives

Abstract

A method is provided for detection of birefringent particles in a blood sample from a subject. The blood sample is processed to lyse red blood cells and the processed blood sample is imaged using an optical microscope configured for back scattering dark field microscopy. The imaging comprises illuminating the processed blood sample with light having a first polarisation state, capturing an image of light scattered by the processed blood sample having a second polarisation state different from the first polarisation state, and analysing the image to identify birefringent particles. Either a magnification of the optical microscope is at most 10x magnification; or a thickness of the processed blood sample is greater than a depth of field of the optical microscope and the imaging further comprises scanning the focal plane of the optical microscope through the thickness of the processed blood sample during the capturing of the image.

IPC Classes  ?

• G01N 15/1434 - Optical arrangements

Abstract

The invention concerns compounds which are useful in targeting and degrading the NUDT5 protein. The invention also concerns the compounds of the invention for use in methods of treatment, particularly for use in treatment of cancer, inflammatory disorders and folate-related disorders, as well as to reduce the side-effects and/or toxicity of a second drug. The invention further concerns screening methods.

IPC Classes  ?

• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 473/08 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

The present invention relates to a transducer for converting mechanical or kinetic energy to electrical energy, wherein the transducer comprises a composite material, wherein the composite material comprises a polymer matrix and, dispersed in the matrix, a metal organic framework (MOF), wherein the metal organic framework comprises a metal ion and an organic linker, wherein the organic linker comprises one or more electronegative substituents.

IPC Classes  ?

• H02N 1/04 - Friction generators
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material

Abstract

Disclosed is a method of processing input data in a processor. The method comprises providing a plurality of radio frequency (RF) signals, each comprising a plurality of RF frequencies with respective component values representing input data, and providing a plurality of optical signals, each optical signal having a respective optical frequency. Each optical signal is modulated with one of the RF signals to generate modulated optical signals. Processing operations are performed on the modulated optical signals in parallel to derive a processor output. Also disclosed is a processor for processing input data according to the method.

IPC Classes  ?

• G06E 3/00 - Devices not provided for in group , e.g. for processing analogue or hybrid data
• G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means

Abstract

The invention relates to enhancing target pMHC discrimination of T cells by modulating the amount of expression and/or activity of factors associated with T cell receptor (TCR) kinetic proofreading.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

109 ABSTRACT The invention relates to an antibody or antigen binding fragment thereof which is capable of binding to CD1a. The antibody or antigen binding fragment thereof may be chimeric or humanised, and may be used to treat one or more inflammatory skin or mucosal disorder, or disease or one or more associated systemic disease or disorder, or one or more inflammatory drug reaction which manifests systemically, or a CD1a-expressing malignancy. To be accompanied by Figure 25 when published.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/00 - Medicinal preparations containing antigens or antibodies